EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Colchicine in COVID‐19: Mechanistic Insights and Clinical Uncertainties

Abrar S Alsulami, Hayder M Al-Kuraishy iD, Tasnim S Waheeb iD, Gaber El-Saber Batiha iD

Reviews in Medical Virology · 2026-03 · 36 (2)

DOI: 10.1002/rmv.70126 ↗

At a glance

Übersichtsarbeit in Reviews in Medical Virology, published online on 2026-03-03. Written by Abrar S Alsulami and 3 co-authors. Institution: Department of Microbiology, College of Medicine, Taif University, Taif, Saudi Arabia. Major MEDLINE topics: Colchicine, COVID-19 Drug Treatment. 113 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Coronavirus Disease 2019 (COVID‐19) which caused by the novel coronavirus SARS‐CoV‐2 has been emerged as a global health crisis characterised by severe immune dysregulation and inflammatory complications. The hyper‐activation of the immune response in COVID‐19 patients is associated with disease progression and severity. As a result, immunomodulatory therapies such as colchicine have been suggested to control exaggerated immune response in COVID‐19. However, the therapeutic role of colchicine in COVID‐19 remains a subject of debate due to conflicting evidence. This review highlights both the beneficial and potentially harmful effects of colchicine in the context of COVID‐19. Notably, the therapeutic advantages of colchicine are linked to the suppression of immune cell over‐activation, attenuation of oxidative stress, and prevention of thrombo‐inflammatory events. Conversely, colchicine may exert negative effects by disrupting microtubule function, impairing autophagic processes, and inducing mitochondrial dysfunction in COVID‐19. In conclusion, the overall clinical impact of colchicine plays a critical role in the management of COVID‐19. However, its dual effects underscore the need for well‐designed clinical studies to confirm its safety and efficacy in COVID‐19 management.

Subjects

MeSH terms (MEDLINE)

ColchicineCOVID-19 Drug TreatmentHumansCOVID-19SARS-CoV-2AutophagyOxidative Stress

Author keywords

COVID‐19SARS‐CoV‐2colchicinecytokine stormimmunomodulationinflammation

Substances

Colchicine

Authors and institutions

  • Department of Microbiology, College of Medicine, Taif University, Taif, Saudi Arabia.
  • Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
  • Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt.
  • Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.

ORCID profiles: Hayder M Al-Kuraishy, Tasnim S Waheeb, Gaber El-Saber Batiha

Cite

APA

Alsulami, A. S., Al-Kuraishy, H. M., Waheeb, T. S., & El-Saber Batiha, G. (2026). Colchicine in COVID‐19: Mechanistic Insights and Clinical Uncertainties. Reviews in Medical Virology, 36(2). https://doi.org/10.1002/rmv.70126

Vancouver

Alsulami AS, Al-Kuraishy HM, Waheeb TS, El-Saber Batiha G. Colchicine in COVID‐19: Mechanistic Insights and Clinical Uncertainties. Reviews in Medical Virology. 2026;36(2). doi:10.1002/rmv.70126

BibTeX
@article{Alsulami2026,
  author = {Alsulami, Abrar S and Al-Kuraishy, Hayder M and Waheeb, Tasnim S and El-Saber Batiha, Gaber},
  title = {Colchicine in COVID‐19: Mechanistic Insights and Clinical Uncertainties},
  journal = {Reviews in Medical Virology},
  year = {2026},
  volume = {36},
  number = {2},
  doi = {10.1002/rmv.70126}
}
Start for free →